DYN (Dyne Therapeutics) Pre-Tax Income : $-317.42 Mil (TTM As of Dec. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Dyne Therapeutics Pre-Tax Income?

Pretax income is the income that a company earns before paying income taxes. Dyne Therapeutics's pretax income for the three months ended in Dec. 2024 was $-89.54 Mil. Its pretax income for the trailing twelve months (TTM) ended in Dec. 2024 was $-317.42 Mil. Dyne Therapeutics's pretax margin was %.

Dyne Therapeutics Pre-Tax Income Historical Data

The historical data trend for Dyne Therapeutics's Pre-Tax Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dyne Therapeutics Pre-Tax Income Chart

Dyne Therapeutics Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Pre-Tax Income

Get a 7-Day Free Trial

-59.44

-149.29

-168.10

-235.94

-317.42

Dyne Therapeutics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Pre-Tax Income	Get a 7-Day Free Trial															-66.64	-65.65	-65.10	-97.13	-89.54

Competitive Comparison of Dyne Therapeutics's Pre-Tax Income

For the Biotechnology subindustry, Dyne Therapeutics's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Dyne Therapeutics's Pre-Tax Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Dyne Therapeutics's Pre-Tax Income distribution charts can be found below:

* The bar in red indicates where Dyne Therapeutics's Pre-Tax Income falls into.

Dyne Therapeutics Pre-Tax Income Calculation

This is the income that a company earns before paying income taxes.

Dyne Therapeutics's Pretax Income for the fiscal year that ended in Dec. 2024 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-343.886	+	-0.454	+	0	+	26.922	+	0
	=	-317.42

Dyne Therapeutics's Pretax Income for the quarter that ended in Dec. 2024 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-97.108	+	-0.026	+	0	+	7.592	+	0
	=	-89.54

Pre-Tax Income for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-317.42 Mil.

Dyne Therapeutics (NAS:DYN) Pre-Tax Income Explanation

Dyne Therapeutics's Pretax Margin for the quarter that ended in Dec. 2024 is calculated as

Pretax Margin	=	Pretax Income	/	Revenue
	=	-89.542	/	0
	=	%

Dyne Therapeutics Pre-Tax Income Related Terms

Thank you for viewing the detailed overview of Dyne Therapeutics's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Dyne Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Dyne Therapeutics Inc (NAS:DYN) » Definitions » Pre-Tax Income

Comparable Companies

Traded in Other Exchanges

N/A

Address

1560 Trapelo Road, Waltham, MA, USA, 02451

Website

https://www.dyne-tx.com

Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease are seeking to treat, a linker, and an antigen-binding fragment, that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.

Executives

Richard William Scalzo	officer: See Remarks	25 ALBERTA LANE, HOLLISTON MA 01746
Oxana Beskrovnaya	officer: See Remarks	C/O DYNE THERAPEUTICS, INC., 830 WINTER STREET, WALTHAM MA 02451
Dirk Kersten	director, 10 percent owner	C/O FORBION CAPITAL FUND IV COOPERATIEF, GOOMIER 2-35, NAARDEN P7 14111 DC
Carlo Incerti	director	FORBION CAPITAL FUND IV COOPERAITEF U.A., GOOMIER 2-35, NAARDEN P7 1411DC
Jason P Rhodes	director, 10 percent owner	C/O EPIZYME, INC., 400 TECHNOLOGY SQUARE, 4TH FLOOR, CAMBRIDGE MA 02139
Susanna Gatti High	officer: Chief Operating Officer	75 LORIMER ROAD, BELMONT MA 02141
Wildon Farwell	officer: Chief Medical Officer	C/O DYNE THERAPEUTICS, INC., 830 WINTER STREET MA 02451
Jonathan Mcneill	officer: See Remarks	C/O DYNE THERAPEUTICS, INC., 830 WINTER STREET, WALTHAM MA 02451
Joshua T Brumm	director, officer: See Remarks	ZELTIQ AESTHETICS INC., 4698 WILLOW ROAD SUITE 100, PLEASANTON CA 94588
Atlas Venture Opportunity Fund I, L.p.	10 percent owner	400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139
Atlas Venture Fund Xi, L.p.	10 percent owner	400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139
Atlas Venture Associates Opportunity Ii, Lp	10 percent owner	300 TECHNOLOGY SQUARE, 8TH FLOOR, CAMBRIDGE MA 02139
Atlas Venture Opportunity Fund Ii, L.p.	10 percent owner	300 TECHNOLOGY SQUARE, 8TH FLOOR, CAMBRIDGE MA 02139
Atlas Venture Associates Opportunity Ii, Llc	10 percent owner	300 TECHNOLOGY SQUARE, 8TH FLOOR, CAMBRIDGE MA 02139
Romesh Subramanian	10 percent owner, officer: Chief Scientific Officer	C/O DYNE THERAPEUTICS, INC., 830 WINTER STREET, WALTHAM MA 02451